{"id":"https://openalex.org/W7221593301","doi":"https://doi.org/10.3389/fimmu.2026.2013615","title":"Editorial: Beyond conventional biomarkers: unlocking immunotherapy response through novel biomarkers or combinatorial approaches","display_name":"Editorial: Beyond conventional biomarkers: unlocking immunotherapy response through novel biomarkers or combinatorial approaches","publication_year":2026,"publication_date":"2026-10-13","ids":{"openalex":"https://openalex.org/W7221593301","doi":"https://doi.org/10.3389/fimmu.2026.2013615","pmid":"https://pubmed.ncbi.nlm.nih.gov/42947911","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13710389"},"language":"en","primary_location":{"id":"doi:10.3389/fimmu.2026.2013615","doi":"https://doi.org/10.3389/fimmu.2026.2013615","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.2013615","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.2013615/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"volume":null,"type":"editorial","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.2013615/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023278790","display_name":"\u00dcnal Metin Tokat","orcid":"https://orcid.org/0000-0003-0026-368X","observed_orcids":["https://orcid.org/0000-0003-0026-368X"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"\u00dcnal Metin Tokat","raw_affiliation_strings":["Precision Oncology Center, Medicana Health Group"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Precision Oncology Center, Medicana Health Group","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080942189","display_name":"Nalan Akg\u00fcl Babacan","orcid":"https://orcid.org/0000-0001-6006-4290","observed_orcids":["https://orcid.org/0000-0001-6006-4290"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nalan Akgul Babacan","raw_affiliation_strings":["Precision Oncology Center, Medicana Health Group"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Precision Oncology Center, Medicana Health Group","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5002254032","display_name":"Mutlu Demiray","orcid":"https://orcid.org/0000-0003-2501-3097","observed_orcids":["https://orcid.org/0000-0003-2501-3097"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Mutlu Demiray","raw_affiliation_strings":["Precision Oncology Center, Medicana Health Group"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Precision Oncology Center, Medicana Health Group","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5002254032","https://openalex.org/A5023278790"],"corresponding_institution_ids":[],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":"2013615","last_page":"2013615"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11355","display_name":"Inflammatory Biomarkers in Disease Prognosis","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immunotherapy-response-biomarkers","display_name":"immunotherapy response biomarkers","score":0.9309999942779541},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8100000023841858},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.8050000071525574},{"id":"https://openalex.org/keywords/glioblastoma","display_name":"glioblastoma","score":0.9599999785423279},{"id":"https://openalex.org/keywords/liquid-biopsy","display_name":"liquid biopsy","score":0.8199999928474426},{"id":"https://openalex.org/keywords/spatial-multi-omics","display_name":"spatial multi-omics","score":0.9079999923706055},{"id":"https://openalex.org/keywords/radiogenomics","display_name":"radiogenomics","score":0.9879999756813049},{"id":"https://openalex.org/keywords/long-non-coding-rna","display_name":"long non-coding RNA","score":0.8209999799728394},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8389999866485596},{"id":"https://openalex.org/keywords/small-cell-lung-cancer","display_name":"small cell lung cancer","score":0.8949999809265137},{"id":"https://openalex.org/keywords/cervical-cancer","display_name":"cervical cancer","score":0.7710000276565552},{"id":"https://openalex.org/keywords/circulating-tumor-dna","display_name":"circulating tumor DNA","score":0.49300000071525574},{"id":"https://openalex.org/keywords/neutrophil-to-lymphocyte-ratio","display_name":"neutrophil-to-lymphocyte ratio","score":0.8009999990463257},{"id":"https://openalex.org/keywords/platelet-to-lymphocyte-ratio","display_name":"platelet-to-lymphocyte ratio","score":0.9200000166893005},{"id":"https://openalex.org/keywords/cortisol","display_name":"cortisol","score":0.6050000190734863},{"id":"https://openalex.org/keywords/lactate","display_name":"lactate","score":0.6430000066757202},{"id":"https://openalex.org/keywords/pyruvate","display_name":"pyruvate","score":0.8539999723434448},{"id":"https://openalex.org/keywords/metabolic-biomarkers","display_name":"metabolic biomarkers","score":0.5170000195503235},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.5899999737739563},{"id":"https://openalex.org/keywords/immunotherapy-resistance","display_name":"immunotherapy resistance","score":0.5699999928474426},{"id":"https://openalex.org/keywords/chemoimmunotherapy","display_name":"chemoimmunotherapy","score":0.6800000071525574}],"concepts":[{"id":"https://openalex.org/C2780790343","wikidata":"https://www.wikidata.org/wiki/Q5090610","display_name":"Chemoimmunotherapy","level":4,"score":0.765500009059906},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.746999979019165},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.6205999851226807},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.5709999799728394},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5604000091552734},{"id":"https://openalex.org/C34626388","wikidata":"https://www.wikidata.org/wiki/Q721129","display_name":"Nomogram","level":2,"score":0.5367000102996826},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4724000096321106},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.4697999954223633},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4169999957084656},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.35519999265670776},{"id":"https://openalex.org/C2778319317","wikidata":"https://www.wikidata.org/wiki/Q22327449","display_name":"Ferritin","level":2,"score":0.3434000015258789},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.33880001306533813},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.3337000012397766},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3321000039577484},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.31060001254081726},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.3059999942779541},{"id":"https://openalex.org/C2779529041","wikidata":"https://www.wikidata.org/wiki/Q22349364","display_name":"Liquid biopsy","level":3,"score":0.28780001401901245},{"id":"https://openalex.org/C2780108502","wikidata":"https://www.wikidata.org/wiki/Q4915018","display_name":"Biological response modifiers","level":3,"score":0.2777999937534332},{"id":"https://openalex.org/C124535831","wikidata":"https://www.wikidata.org/wiki/Q4915074","display_name":"Biomarker discovery","level":4,"score":0.2750999927520752},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.2603999972343445},{"id":"https://openalex.org/C2909316934","wikidata":"https://www.wikidata.org/wiki/Q2100344","display_name":"Podoplanin","level":3,"score":0.2547000050544739},{"id":"https://openalex.org/C163763905","wikidata":"https://www.wikidata.org/wiki/Q17075943","display_name":"Precision medicine","level":2,"score":0.25360000133514404},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.2535000145435333},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.25099998712539673}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.3389/fimmu.2026.2013615","doi":"https://doi.org/10.3389/fimmu.2026.2013615","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.2013615","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.2013615/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13710389","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13710389/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13710389/pdf/fimmu-17-2013615.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Immunol","raw_type":"Text"},{"id":"pmid:42947911","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42947911","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in immunology","raw_type":"Editorial"},{"id":"pmh:oai:doaj.org/article:d8820176cd7a4be285b1ee86326a9b52","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/d8820176cd7a4be285b1ee86326a9b52","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Immunology, Vol 17 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fimmu.2026.2013615","doi":"https://doi.org/10.3389/fimmu.2026.2013615","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.2013615","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.2013615/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7221593301.pdf","grobid_xml":"https://content.openalex.org/works/W7221593301.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4388300693","https://openalex.org/W7160325400","https://openalex.org/W4298008223","https://openalex.org/W4386812704","https://openalex.org/W4281569520","https://openalex.org/W4399578568","https://openalex.org/W4393944935","https://openalex.org/W7165160440","https://openalex.org/W7219896785","https://openalex.org/W7154708406"],"abstract_inverted_index":{"Three":[0],"reviews":[1,117],"in":[2,10,37,61,135,173,252,270,337,456,475,503,560,583,606,627,649,664,689,705,721,790,840,873,938,997,1115],"this":[3,525,791,1032],"research":[4,1033],"topic":[5,137,1034],"outlined":[6],"the":[7,11,38,55,92,96,136,146,154,185,299,338,480,487,540,543,690,706,738,991,1023,1028,1038,1083],"current":[8],"challenges":[9,479],"field.":[12],"Across":[13],"15":[14],"studies,":[15],"Ismail":[16],"and":[17,58,69,87,111,132,159,168,216,228,241,249,287,318,348,355,383,422,464,496,501,507,514,528,537,563,581,599,615,624,672,700,718,770,811,822,849,877,894,1013,1059,1067,1087,1094,1103,1127,1144],"Hassan":[18],"found":[19],"that":[20,482,549,836,960,981,1003,1036,1098],"ICI":[21,112,442,468,544,761,850],"combinations":[22],"could":[23,183,267,277,290,434,558,577,637,736,780,869],"prolong":[24],"survival":[25,110,169,230,320],"but":[26,415,763,903],"increased":[27],"severe":[28],"immune-related":[29],"adverse":[30],"events,":[31],"which":[32,658,692],"routinely":[33],"exceed":[34],"those":[35,825],"reported":[36],"clinical":[39,93,687,1129],"trials":[40,1096],"(1).":[41],"Furthermore,":[42,1090],"conventional":[43,186,686],"efficacy":[44,1141],"biomarkers":[45,60,636,688,794,1012],"do":[46],"not":[47,196,416,773],"reliably":[48,278],"predict":[49,163,466,728],"toxicity.":[50],"Kim":[51],"et":[52,99,143,204,245,303,342,408,445,491,546,591,654,714,804,833,925],"al.":[53,100,144,205,246,304,343,409,446,492,547,592,655,715,805,834,926],"examined":[54],"immunotherapy":[56,300,651,703,871,1043,1112],"response":[57,113,166,227,421,469,623,682,762,809,872,910],"resistance":[59,1113],"glioblastoma":[62],"(GBM),":[63],"proposing":[64],"liquid":[65,363,1054],"biopsies,":[66],"spatial":[67,782,1066],"multiomics":[68],"radiogenomics":[70],"to":[71,90,109,162,273,350,372,523,539,554,643,695,727,795,814,919,1031,1135],"address":[72],"intratumoral":[73],"heterogeneity":[74],"beyond":[75,911,1046],"PD-L1":[76,473],"or":[77,188,259,1074],"TMB":[78,813,966],"alone":[79,192,830],"(2).":[80],"These":[81,375,1000],"approaches":[82,576,868],"should":[83,772],"be":[84,268,435,578,774,1133],"rigorously":[85],"tested":[86],"systematically":[88],"validated":[89],"change":[91],"management":[94],"of":[95,313,334,380,542,740,853,993,1025,1041,1077,1085],"GBM":[97],"patients.Alshamlani":[98],"reviewed":[101],"31":[102],"studies":[103,272,379,789,1081],"linking":[104],"long":[105],"non-coding":[106],"RNA":[107,787],"signatures":[108,779],"(3).":[114],"Together,":[115],"these":[116,633,1080,1120],"support":[118,845],"dynamic,":[119],"multimodal":[120],"biomarker":[121,235,439],"development":[122],"assisted":[123],"by":[124,401,828],"artificial":[125],"intelligence,":[126],"with":[127,157,224,420,511,620,759,784,856,883,891,931,957],"separate":[128],"models":[129,282,1124],"for":[130,256,298,325,440,679,747,1149],"benefit":[131,769],"harm.Several":[133],"articles":[134],"explored":[138,865],"accessible":[139,641],"circulating":[140,346],"measures.":[141],"Xie":[142],"introduced":[145,656],"Lung":[147],"Cancer":[148],"Immune":[149],"Prognostic":[150],"Score":[151],"(LCIPS),":[152],"combining":[153],"albumin-to-globulin":[155],"ratio":[156,598],"monocyte":[158],"lymphocyte":[160,613],"counts":[161],"pathological":[164],"complete":[165,908],"(pCR)":[167],"after":[170,730],"neoadjuvant":[171,731],"chemoimmunotherapy":[172,226,336,732],"non-small":[174],"cell":[175,668,711,944,955],"lung":[176,201],"cancer":[177,262,328,609,843,1042],"(NSCLC)":[178],"(4).":[179],"This":[180,233,264,734],"novel":[181],"tool":[182,746],"complement":[184,642],"markers":[187,289,371],"offer":[189],"an":[190,310,515,551,674,722,880,932],"insight":[191],"when":[193],"they":[194,1020],"are":[195],"available.":[197],"In":[198,330,404,586,708,798],"extensive-stage":[199],"small-cell":[200],"cancer,":[202,802],"Liu":[203,341],"assessed":[206,269],"ferritin":[207,215],"changes":[208],"alongside":[209,1107],"inflammatory":[210,265],"markers,":[211],"associating":[212],"low":[213,616],"baseline":[214],"a":[217,253,331,361,392,436,448,587,639,744,846,907,923,973],"significant":[218],"decrease":[219],"during":[220,322,426],"treatment":[221,324,768],"(high":[222],"\u0394SF)":[223],"better":[225,351,621,826],"progression-free":[229],"(PFS)":[231],"(5).":[232],"cost-effective":[234],"panel":[236],"also":[237,377],"bridges":[238],"iron":[239,381],"metabolism":[240,382],"antitumor":[242],"immunity.":[243],"Wang":[244,713],"used":[247],"neutrophil-to-lymphocyte":[248],"platelet-to-lymphocyte":[250],"ratios":[251],"prognostic":[254],"nomogram":[255],"immunotherapy-treated":[257],"recurrent":[258,884],"metastatic":[260,939],"cervical":[261,506],"(6).":[263],"signature":[266,450],"prospective":[271,332,1126],"confirm":[274],"if":[275,866],"we":[276],"integrate":[279],"such":[280],"combinatorial":[281,867,995,1095],"into":[283,1125],"precision":[284],"immuno-oncology":[285],"workflows.Metabolic":[286],"hormonal":[288],"similarly":[291],"serve":[292],"as":[293,309,391,776],"complementary":[294],"and/or":[295],"independent":[296,311],"predictors":[297],"response.":[301],"Zhao":[302],"identified":[305],"elevated":[306],"pretreatment":[307],"cortisol":[308],"marker":[312,424],"poorer":[314,764],"disease":[315,352,929],"control,":[316,353],"PFS":[317,354,562,671],"overall":[319],"(OS)":[321],"anti-PD-1":[323],"advanced":[326,505,607,665,799],"gastric":[327],"(7).":[329],"study":[333,359],"first-line":[335,819],"same":[339],"disease,":[340],"linked":[344,553],"lower":[345],"lactate":[347],"pyruvate":[349],"OS":[356,564],"(8).":[357],"The":[358],"highlights":[360],"novel,":[362],"biopsybased":[364],"approach,":[365],"shifting":[366],"focus":[367],"from":[368,451,661,818,824,1071,1122,1142],"traditional":[369,741],"tissue":[370],"metabolic":[373,976,1058],"profiling.":[374],"observations":[376],"motivate":[378],"glucocorticoid":[384],"receptor":[385],"modulation,":[386],"without":[387],"yet":[388],"establishing":[389],"either":[390],"therapeutic":[393,796],"strategy.Circulating":[394],"immune":[395,485,519,920,984,1005,1061,1101],"cells":[396,455],"may":[397,1007],"reveal":[398],"information":[399],"missed":[400],"soluble":[402],"markers.":[403],"hepatocellular":[405],"carcinoma,":[406,669,712],"Lu":[407],"associated":[410],"IFN-\u03b3-producing":[411],"cytotoxic":[412],"lymphocytes":[413],"(CTLs),":[414],"serum":[417],"IFN-\u03b3":[418],"levels,":[419],"tumor":[423,600,945],"decline":[425],"PD-(L)1":[427],"therapy":[428],"(9).":[429],"Thus,":[430],"IFN\u03b3":[431],"+":[432],"CTLs":[433],"new":[437],"cellular":[438],"predicting":[441],"efficacy.":[443],"Schmidt":[444],"developed":[447],"machine-learning":[449],"peripheral":[452,1060],"CD8+":[453],"T":[454],"NSCLC":[457],"(10);":[458],"effector":[459],"memory":[460],"features,":[461],"including":[462,498,626],"CD44":[463],"GIMAP4,":[465],"long-term":[467],"more":[470],"accurately":[471],"than":[472],"TPS":[474],"their":[476],"cohort.Longitudinal":[477],"profiling":[478,1076],"assumption":[481],"non-response":[483],"reflects":[484],"inactivity.In":[486],"PRIMMO":[488],"trial,":[489],"Baiden-Amissah":[490],"describe":[493],"concurrent":[494],"activation":[495],"regulation,":[497],"CD69,":[499],"ICOS":[500],"Tregs,":[502],"nonresponding":[504],"endometrial":[508],"cancers":[509],"treated":[510,775,890],"pembrolizumab,":[512,892],"radiotherapy":[513],"immunomodulatory":[516],"cocktail":[517],"(11).Longitudinal":[518],"monitoring":[520],"is":[521,693],"required":[522],"track":[524],"dynamic":[526,1057],"equilibrium":[527],"tailor":[529],"adaptive":[530,1128],"combination":[531],"regimens.Host":[532],"genetics":[533],"adds":[534],"another":[535],"perspective":[536],"complexity":[538],"prediction":[541],"response.Watanabe":[545],"demonstrated":[548],"HLA-DRB1*04:05,":[550],"allele":[552],"type":[555],"1":[556],"diabetes,":[557],"result":[559],"shorter":[561],"among":[565],"Japanese":[566],"patients":[567,816,1150],"receiving":[568],"ICIs,":[569],"supporting":[570],"further":[571],"population-specific":[572],"immunogenetic":[573,1075],"assessment":[574],"(12).Tissue-based":[575],"equally":[579],"relevant":[580],"important":[582],"some":[584],"contexts.":[585],"multicenter":[588],"study,":[589,691],"Chen":[590],"evaluated":[593],"stromal":[594,617],"tumor-infiltrating":[595],"lymphocytes,":[596],"tumor-stroma":[597],"budding":[601],"on":[602,948],"routine":[603,1072],"H&E":[604,662],"slides":[605,663],"colorectal":[608],"(CRC)":[610],"(13).":[611],"High":[612],"infiltration":[614],"content":[618],"correlated":[619],"objective":[622],"PFS,":[625],"mismatch":[628],"repair-proficient":[629],"(pMMR)":[630],"tumors.":[631,999,1117],"Standardizing":[632],"costeffective":[634],"morphological":[635],"provide":[638],"highly":[640],"molecular":[644],"testing,":[645],"improving":[646],"patient":[647,748,882],"stratification":[648,704],"real-world":[650],"settings.":[652],"Chayen":[653],"ENLIGHT-DP,":[657],"infers":[659],"transcriptomics":[660],"cutaneous":[666],"squamous":[667,710,958],"stratifying":[670],"achieving":[673],"84.2%":[675],"positive":[676],"predictive":[677,1138],"value":[678],"PD-1":[680,936],"inhibitor":[681],"(14).":[683],"It":[684],"outperformed":[685],"promising":[694],"bypass":[696],"resource-intensive":[697],"genomic":[698],"testing":[699,1015],"streamline":[701],"personalized":[702,1147],"future.":[707],"esophageal":[709],"combined":[716],"endoscopic":[717],"hematological":[719],"data":[720],"interpretable":[723],"random-forest/machine":[724],"learning":[725],"model":[726],"pCR":[729],"(15).":[733],"approach":[735],"overcome":[737],"limitations":[739],"imaging,":[742],"offering":[743],"robust":[745,1137],"stratification.":[749],"(16).":[750],"Their":[751],"7-gene":[752],"NTRG":[753],"score":[754],"paradoxically":[755],"associates":[756],"higher":[757],"values":[758],"greater":[760],"OS,":[765],"illustrating":[766],"why":[767],"prognosis":[771],"interchangeable.":[777],"Such":[778],"connect":[781,793],"biology":[783],"single-sample":[785],"bulk":[786],"sequencing.Other":[788],"section":[792],"choices.":[797],"biliary":[800],"tract":[801],"He":[803],"utilized":[806],"DNA":[807],"damage":[808],"alterations":[810],"high":[812,988],"distinguish":[815],"benefiting":[817],"sintilimab,":[820],"anlotinib":[821],"gemcitabine/cisplatin":[823],"served":[827],"chemotherapy":[829],"(17).":[831],"Crossman":[832],"report":[835,927],"tumor-bound":[837],"MerTK":[838],"overexpression":[839],"triple-negative":[841],"breast":[842],"can":[844,986,1109],"pro-inflammatory":[847],"microenvironment":[848],"sensitivity":[851],"irrespective":[852],"PD-L1,":[854],"contrasting":[855],"its":[857],"usual":[858],"immunosuppressive":[859],"role":[860],"(18).Finally,":[861],"three":[862],"case":[863,1092],"reports":[864,1093],"enhance":[870],"treatment-refractory":[874],"setting.":[875],"Yu":[876],"Li":[878],"described":[879,952],"85-year-old":[881],"MSI-high/mismatch":[885],"repair-deficient,":[886],"BRAF":[887],"V600E-mutant":[888],"CRC":[889],"dabrafenib":[893],"trametinib":[895],"(19).":[896],"Severe":[897],"pyrexia":[898],"prompted":[899],"early":[900],"targetedtherapy":[901],"discontinuation,":[902],"pembrolizumab":[904,970],"maintenance":[905],"sustained":[906],"radiographic":[909],"26":[912],"months.":[913],"Whether":[914,1050],"brief":[915],"MAPK":[916],"inhibition":[917],"contributed":[918],"priming":[921],"remains":[922],"hypothesis.Wang":[924],"durable":[928,974],"control":[930],"VEGFR":[933],"TKI":[934],"plus":[935,969],"blockade":[937],"TSC2-mutant":[940],"malignant":[941],"perivascular":[942],"epithelioid":[943],"(PEComa)":[946],"progressing":[947],"everolimus":[949],"(20).Our":[950],"group":[951],"PTCH1-mutant":[953],"basal":[954],"carcinoma":[956],"differentiation":[959],"resisted":[961],"dual":[962],"ICIs":[963,1108],"despite":[964,1010],"ultra-high":[965],"(21).":[967],"Vismodegib":[968],"subsequently":[971],"produced":[972],"near-complete":[975],"remission.":[977],"Our":[978],"work":[979],"demonstrates":[980,1097],"oncogenic":[982],"pathway-mediated":[983],"exclusion":[985,1006,1102],"override":[987],"antigenicity,":[989],"highlighting":[990],"necessity":[992],"biology-guided":[994],"strategies":[996],"biomarker-discordant":[998,1116],"cases":[1001],"suggest":[1002],"pathway-driven":[1004],"limit":[1008],"responses":[1009],"favorable":[1011],"justify":[1014],"targeted":[1016],"therapy-ICI":[1017],"combinations.":[1018],"However,":[1019],"cannot":[1021],"explain":[1022],"contribution":[1024],"individual":[1026],"drugs.Overall,":[1027],"diverse":[1029,1152],"contributions":[1030],"demonstrate":[1035],"unlocking":[1037],"full":[1039],"potential":[1040],"requires":[1044],"moving":[1045],"single,":[1047],"static":[1048],"biomarkers.":[1049],"through":[1051],"minimally":[1052],"invasive":[1053],"biopsies":[1055],"capturing":[1056],"changes,":[1062],"digital":[1063],"pathology":[1064],"inferring":[1065],"transcriptomic":[1068],"landscapes":[1069],"directly":[1070],"histology,":[1073],"host":[1078],"factors,":[1079],"highlight":[1082],"power":[1084],"integrative":[1086],"multidimensional":[1088],"approaches.":[1089],"translational":[1091],"understanding":[1099],"oncogene-mediated":[1100],"strategically":[1104],"targeting":[1105],"it":[1106],"successfully":[1110],"mitigate":[1111],"even":[1114],"Ultimately,":[1118],"transitioning":[1119],"discoveries":[1121],"exploratory":[1123],"trial":[1130],"designs":[1131],"will":[1132],"critical":[1134],"establish":[1136],"frameworks,":[1139],"uncouple":[1140],"toxicity,":[1143],"deliver":[1145],"truly":[1146],"IO":[1148],"across":[1151],"malignancies.":[1153]},"counts_by_year":[],"updated_date":"2026-11-01T11:40:01.658920","created_date":"2026-10-14T00:00:00"}